Biostem Technologies (BSEM) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $74.5 million and first half 2024 revenue of $116.4 million, a dramatic increase from the prior year, driven by strong commercial performance of AmnioWrap2 and a major distribution agreement.

• Net income for Q2 2024 was $6.4 million, with first half net income at $9.6 million, compared to losses in the prior year.

• Gross profit for Q2 was $70.7 million (95% margin), and for the first half $110.4 million, reflecting high profitability.

• Strategic priorities include substantiating BioRetain technology through clinical trials, peer-reviewed publications, and preparing for reimbursement landscape changes.

• Announced plans to uplist to NASDAQ and become a fully reporting SEC entity to increase visibility and liquidity.

Financial highlights

• Q2 2024 net revenue was $74.5 million, up from $1.0–$1.1 million in Q2 2023; first half 2024 revenue was $116.4 million, up from $1.6 million.

• Gross margin for Q2 and first half 2024 was 95%, up from 81–82% in the prior year.

• Operating expenses rose to $61.9 million in Q2, mainly from workforce expansion, distributor fees, and share-based compensation.

• Adjusted Q2 2024 EBITDA was $10 million (13–13.4% margin), compared to a $1.3 million loss in the previous year.

• Cash position increased to $6.6 million at June 30, 2024, up from $239K at year-end.

Outlook and guidance

• Optimistic outlook for 2024, with robust market demand for advanced wound care and continued product innovation.

• Plans to launch additional clinical studies and expand manufacturing capacity to support future sales growth.

• Anticipates modest increase in R&D spend as a percentage of net revenue, with ongoing investments in clinical trials and product development.

• Uplisting to NASDAQ expected within 60–90 days, pending SEC and NASDAQ review.